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Abstract
Background: We investigated the genotypic distribu-
tion of Hpdel in healthy subjects and cancer patients
in Taiwan.
Methods: Blood samples were collected from 244 ran-
domly selected healthy Taiwanese volunteers and 737
patients with various cancers. Samples were analyzed
for the haptoglobin (Hp) gene, and the presence of the
Hpdel allele was determined from genomic DNA by an
Hpdel-specific polymerase chain reaction (PCR) meth-
od. The plasma concentration of Hp was also
determined.
Results: The frequency of the Hpdel allele was calcu-
lated to be 0.029, and was not different between the
healthy subjects and patients with cancer. The prev-
alence of Hp deficiency caused by Hpdel homozygo-
sity was estimated to be ;0.85 in 1000. Fifty-seven
subjects were reclassified from homozygous Hp1 or
Hp2 to Hp1/Hpdel or Hp2/Hpdel genotypes. The Hpdel
allele is not associated with prevalence, severity or
stage of any cancer.
Conclusions: Congenital Hp deficiency caused by
Hpdel homozygosity is a condition present in Taiwan
with a relatively high frequency. However, the Hpdel
variant does not play a role in cancer.
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Introduction
Haptoglobin (Hp) is a plasma glycoprotein which
binds to hemoglobin to prevent iron loss and kidney
damage during hemolysis. It is an acute phase protein
with several functional properties, including antioxi-
dant and anti-inflammatory activities, and regulation
of the immune system. These different properties are
thought to be related to polymorphisms in the Hp
gene, which have been shown to be associated with
a variety of human disorders (1, 2). An understanding
of the distribution of Hp genotypes could help predict
or prevent associated disorders, assess prognosis
and enable optimal treatment.
Humans have genetic polymorphisms of Hp due to
two co-dominant alleles, Hp1 and Hp2. Combinations
of these alleles result in three major phenotypes (Hp
1-1, Hp 2-1, and Hp 2-2). Recently, the Hp0 allele, an
allele deletion in the Hp gene cluster, has been iden-
tified (3, 4). Hp gene analysis has shown that these
individuals are homozygous for a deleted allele of the
Hp gene, Hpdel, which is a deletion of ;28 kb in Hp.
This deletion includes the promoter region and all of
the Hp exons (3, 4). Interestingly, Hpdel has not been
reported in some African and European-African pop-
ulations (4–7), suggesting that the distribution of the
Hpdel allele is limited to individuals of Asian descent,
including Japanese, Koreans, Thais, and Chinese. The
allele frequencies have been shown to differ among
each population, varying between 1.5% and 4.4%
(4–7). The distribution of Hpdel appears to be the high-
est, 3%–4.4%, among the Han Chinese population (5).
Approximately 98% of Taiwanese are Han Chinese,
but no Hp0-0-affected individuals have been found
among the 172 subjects previously studied (8). Also,
there have been no reports examining the allele fre-
quency of the Hpdel variant in Taiwan. Furthermore,
the allele frequency of Hpdel in the Chinese has been
reported to be around 3% (5), suggesting that the
Hpdel should also be high in the Taiwanese
population.
There have also been many reports examining the
association between the Hp phenotype (Hp 1-1, Hp 2-
1, and Hp 2-2) and various cancers (1, 9, 10). One
study reported on the Hp 0-0 phenotype and leukemia
(11). However, association between the Hpdel allele
and other forms of cancer have not been reported.We
studied serum Hp and the Hp genotype in 244 ran-
domly selected healthy subjects and 737 patients with
various types of cancer to determine the Hpdel allele
frequency and its relationship to cancer. The results
obtained in this study will be helpful for understand-
ing the prevalence of Hpdel among the Chinese in
Taiwan, the possible frequency of congenital Hp defi-
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Table 1 Clinical characteristics of major cancer patient group.
Type HNSCC HCC NPC CRC Breast Lung Lymphoma
cancer cancer
Stage*
I 3 7 0 0 6 1 7
II 17 9 2 5 25 2 9
III 13 13 7 35 18 7 15
IV 134 30 39 58 38 37 26
Total 167 69 48 98 87 47 57
Age
Mean 54.83 65.28 50.84 35.87 51.96 63.19 62.38
SD 11.77 10.72 10.42 13.65 10.61 12.43 16.53
Gender
Male 145 45 38 58 0 23 35
Female 22 24 10 40 87 24 22
*Cancer stage was defined as American Joint Committee on Cancer (AJCC) 6th ed., 2002. HNSCC, head and neck squamous
cell carcinoma; HCC, hepatocelluar carcinoma; NPC, nasopharyngeal carcinoma; CRC, colon rectal cancer.
ciency and the association of the Hpdel allele with var-
ious cancer.
Materials and methods
Human subjects
The study was conducted with the approval of our institu-
tional human research Ethics Committees and was in com-
pliance with the procedures for human studies addressed by
the most recent Helsinki Declaration. Written informed con-
sent was obtained from all patients and healthy subjects.
EDTA blood samples were collected from cancer patients
and healthy subjects who were selected at random. Healthy
subjects were excluded if they had known inflammatory con-
ditions such as acute or chronic infection, or major organ
disease, including heart failure, renal failure or liver cirrho-
sis. Clinical characteristics of the cancer patient group,
including clinical stage, age and gender were collected.
Hp genotyping based on polymerase chain
reaction (PCR)
Genomic DNA was extracted from peripheral blood mono-
nuclear cells using a DNA extraction kit (Qiagen, Valencia,
CA, USA). The polymerase chain reaction (PCR) method for
analysis of Hp1 and Hp2 were used as previously described
(9, 12). The specimens noted to be homozygous Hp1 (Hp1/
Hp1) or Hp2 (Hp2/Hp2) were checked by Hpdel genotyping.
Hpdel-specific PCR amplification was performed with the
primers, Hp-del-U and Hp-del-L, according to the methods
described by Koda and co-workers (3, 4). Exon 1 of Hp also
was amplified simultaneously with the primers, Hp-exon-U
and Hp-exon-L, to detect normal Hp.
The oligonucleotide primers, Hp-del-U (59-CTTTATGG-
CACTGGGGAACAAGCATTTTG-39) and Hp-del-L (59-CAG-
GAAGAGATTTTTAGCCGTGGTCAGCAG-39), were used for
amplification of a 315-bp Hpdel allele-specific sequence. The
primers Hp-exon-U (59-GCAGTGTGAAAATCCTCCAAGATAA-
39) and Hp-exon-L (5-AATTTAGCCCATTTGCCCGTTTCTT-39),
were used to amplify a 476-bp Hp1 or Hp2 allele-specific
sequence. PCR was preformed in a final volume of 50 mL,
containing 10–20 ng of genomic DNA. For the PCR protocol,
1X PCR buffer (Qiagen), 1.5 mM MgCl2, 0.2 mM dNTPs, 0.2
mM of each primer, and two units of Qiagen taq DNA poly-
merase were included in the PCR reactions. Thermal cycler
settings used for amplification were as follows: an initial
incubation at 958C for 5 min, followed by 35 cycles of incu-
bation at 958C for 30 s, 608C for 40 s, and 728C for 1 min,
with a final extension at 728C for 10 min. The resulting PCR
products underwent electrophoresis using a 1% agarose gel
and stained with ethidium bromide. The Hpdel-specific PCR
product was detected as a 315-bp band, while the product
of the Hp exon 1 was detected as a 476-bp band.
Statistical analyses
Mean values and SD were calculated. Pearson’s x2-test was
used to evaluate the distribution of the three Hp genotypes
among each group. A p-value -0.05 was used for statistical
significance.
Results
Blood samples were collected from 244 randomly
selected healthy Taiwanese volunteers and 737
patients with various types of cancer. Clinical and
demographic information of patients with the more
common types of cancer, including clinical stage, age
and gender is shown in Table 1. The Hpdel allele was
detected in 57 healthy subjects and cancer patients
using a Hpdel-specific PCR method. Eleven of 94
(11.7%) subjects who were thought to have the Hp1/
Hp1 genotype were re-classified as Hp1/Hpdel. In addi-
tion, 46 of 489 (9.4%) subjects who were thought to
be Hp2/Hp2 were reclassified as a Hp2/Hpdel genotype.
The frequency of the Hpdel allele was determined to
be 0.0292. There was no difference in frequency
between healthy individuals (0.0266) and those with
cancer (0.0298; Table 2). The prevalence of Hp defi-
ciency caused by Hpdel heterozygosity was estimated
to be ;0.85 in 1000 in our cohort. The Hpdel allele
frequencies for patients with cancer are summarized
in Table 3. Patients with lymphoma had the lowest
frequency of Hpdel (0.009), while patients in the ‘other
cancer’ group had the highest frequency (0.041).
There was no significant difference in the Hpdel fre-
quency between healthy individuals and each of the
different cancer groups. In addition, there were no
significant difference in Hpdel frequency between each
of the different cancer groups. We analyzed the
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Table 2 Hp genotype prevalence in healthy controls and patients with cancer.
Total Healthy group Cancer group
(ns981) (ns244) (ns737)
Age (years) 50.8"12.3 51.3"14.1 50.7"11.7
Gender (M/F) 587/394 150/94 437/300
Genotype
Hp1/Hp1 83 (8.5%) 18 (7.4%) 65 (8.8%)
Hp2/Hp1 386 (39.3%) 113 (46.3%) 293 (39.8%)
Hp2/Hp2 416 (42.4%) 100 (40.1%) 335 (45.5%)
Hp1/Hpdel 11 (1.1%) 1 (0.4%) 10 (1.4%)
Hp2/Hpdel 44 (4.5%) 12 (4.9%) 34 (4.6%)
Allele frequency
Hpdel 0.0292 0.0266 0.0298
Hp1 0.299 0.307 0.294
Hp2 0.671 0.6659 0.676
Values are given as number (%). Odds ratio of Hp 2 vs. Hp 1, 1.063; 95% confidence interval, 0.849–1.329; ps0.594.
Table 3 Hpdel genotype distribution and allele frequency in healthy controls and patients with various types of cancers.
Normal HNSCC HCC NPC CRC Breast Lung Leukemia Lymphoma Other
control cancer cancer cancer
Total allele 488 334 138 96 196 174 94 60 114 268
Hpdel allele 13 10 4 2 7 4 3 2 1 11
Hpdel 0.027 0.03 0.029 0.021 0.036 0.023 0.032 0.033 0.009 0.041
frequency
p-Value* – 0.778 0.881 0.742 0.524 0.794 0.775 0.764 0.254 0.201
*Compared with healthy group. HNSCC, head and neck squamous cell carcinoma; HCC, hepatocelluar carcinoma; NPC, naso-
pharyngeal carcinoma; CRC, colon rectal cancer.
Table 4 Hpdel genotype distribution and cancer stage* in patients with various types of cancers.
Type HNSCC HCC NPC CRC Breast Lung Lymphoma
(ns167) (ns69) (ns48) (ns98) cancer cancer (ns57)
(ns87) (ns47)
Stage
I/II 2 (1.2%) 2 (2.9%) 0 0 2 (2.3%) 1 (2.1%) 0
III/IV 8 (4.8%) 2 (2.9%) 2 (4.2%) 7 (9.1%) 2 (2.3%) 2 (4.2%) 1 (1.6%)
p-Value 0.353 0.258 0.910 0.673 0.488 0.115 0.778
*Cancer stage was defined as AJCC 6th ed., 2002. Values are given as number (%). HNSCC, head and neck squamous cell
carcinoma; HCC, hepatocelluar carcinoma; NPC, nasopharyngeal carcinoma; CRC, colon rectal cancer.
clinical stage of the cancer patients with Hpdel and
there was no relationship between the severity of can-
cer as assessed by clinical stage, and the Hpdel geno-
type (Table 4).
Discussion
Frequencies of the Hp1 and Hp2 phenotypes have
been reported to exhibit geographic differences that
are dependent on ethnicity (2). Blackwell and Thep-
husdin conducted a ‘pheonotypic’ study involving 682
healthy adults and reported that the frequency of the
Hp1 phenotype among Thais was ;0.24%, and 2.3%
of Thai individuals have the Hp 0-0 phenotype (13).
Expression of the Hp gene is absent in anhaptoglo-
binemia (Hp 0-0 phenotype); a condition present in 1
in 1000 Caucasians. In blacks, especially of West Afri-
can descent (i.e., Nigeria and Cameroon), anhaptoglo-
binemia is more frequent, reportedly )30% (14, 15).
In the US, the frequency of Hp 0-0 in blacks is consid-
erably less at 4% (15). Hypohaptoglobinemia has also
been reported in a few non-black families carrying a
‘‘silent allele’’ with no gene product (Hp0 phenotype;
2). Hp 0-0 has also been reported in Asians. However,
it should be noted that a complete genetic model has
not yet been reported for the Hp0 phenotype in pop-
ulations other than Asians wHpdel genotype; 3, 5, 6,
(16)x. Teye et al. reported that the A–61C mutation in
the promoter of the Hp gene and another mutation in
exon 7 in the b-chain of the Hp2 allele reduced tran-
scription activity and Hp gene expression (17, 18). In
addition, these mutations seem to be related to some
of the anhaptoglobinemic individuals in Africa (19).
No other detectable change in the Hp gene clusters,
including the promoter region, of Hp0 individuals has
been reported in other areas. Some authors presume
that the reduced expression of Hp is related to the
trans-acting factors necessary for Hp expression, or
cis-acting promoter sequences (20). However, at pres-
ent there is no apparent research to confirm the spec-
ulation in other areas. Blackwell et al. (8) also
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investigated the Hp phenotype among Taiwanese.
Unfortunately, their method was not a genetic survey
by PCR but rather a genotypic survey by electropho-
resis. Thus, the individuals with the heterozygous
allele of Hp0 (Hp1-0 and Hp 2-0) could be misidenti-
fied as Hp 1-1 or Hp 2-2. In our series, the Hp1 allele
frequency (33%) was nearly the same as previously
reported by Blackwell (28%). However, the Hp0 fre-
quency as determined by the PCR method was more
accurate in detecting individuals with Hp0 heterozy-
gosity. Nevertheless, differentiating between congen-
ital and acquired hypohaptoglobinemia could be
difficult. There are many factors that may interfere
with the diagnosis of hypohaptoglobinemia, including
age, underlying congenital diseases such as hemolyt-
ic disorders (e.g., hereditary red cell membrane and
enzyme defects, thalassemia, and sickle cell anemia),
and even lifestyle factors (e.g., repetitive physical
exercise associated with limited mechanical trauma
to erythrocytes). No Hp can be detected in neonatal
serum. However, by the sixth month of life, failure to
detect Hp becomes relatively rare. About 75% of Hp0
subjects with Plasmodium vivax infection, when treat-
ed with chloroquine, showed typable Hp polymorphs
by 8–9 days post-treatment (21). The Hpdel variant has
been detected exclusively in Asians, thus it may rep-
resent the most important cause of Hp0 in this pop-
ulation (5, 19). Therefore, we suggest a genetic survey
as an easier and more accurate method to detect the
Hp0 genotype in the Asians.
Some case reports have examined congenital Hp
deficiency among cases of severe anaphylactic trans-
fusion reactions (22–24). All of these cases occurred
in Japanese who were homozygous for a deleted
allele of the Hp gene, Hpdel. Alloimmunization may
play a role in the development of anaphylactic non-
hemolytic transfusion reactions due to the presence
of both IgG and IgE class anti-haptoglobins, which
have been noted in patient blood (22–24). Transfusion
of Hp-depleted blood products should be considered
in order to avoid such reactions (25). The frequency
of the Hpdel allele among the Taiwanese population
was determined to be 0.03 and the prevalence of Hp
deficiency was estimated to be as high as 1 in 1000.
However, there have been no case reports describing
congenital Hp deficiency among the Chinese. This
may be due to misdiagnosis of many cases of anhap-
toglobin physicians. Patients are not identified as
Hp-deficient until they experience anaphylactic trans-
fusion reactions during the course of treatment for
their diseases, and healthy volunteer donors with Hp
deficiency do not show any pathogenic tendencies.
We have begun a study to survey Hpdel frequency in
patients suffering from severe transfusion reactions in
our hospital. In addition, congenital Hp deficiency
should be one of the major causes of severe trans-
fusion reactions among Chinese as well as other
Asians. In addition, transfusion of Hp-depleted blood
products should be effective in avoiding such reac-
tions. We stress that congenital Hp defi-
ciency is an important risk factor for transfusion in
Chinese.
Serum Hp levels have been reported to be lower in
the subjects of Hp 2-2 than in Hp 1-1 and Hp 2-1 (2,
7, 26). In particular, the Hp2/Hpdel genotype was
reported to be associated with an abnormally low Hp
concentration (3, 6, 7). The physiologic explanation
for this condition needs to be investigated further. It
has been suggested these patients may have a lower
clearance rate for heme and other super-oxidant sub-
stances because of lower Hp levels. This may inter-
fere with the clinical course of their disease. Although
many studies have reported the biological or clinical
importance of Hp in various diseases, including car-
diovascular disease, diabetes, or cancer (2, 27), con-
genital Hp deficiency does not appear to be
associated with any pathologic conditions other than
transfusion reactions. Different biological activity has
been described to account for differences between
Hp1 and Hp2. These include differences in hemoglo-
bin-binding ability, protection against free radicals,
inhibition of prostaglandin synthesis, and bacterio-
static effects. In our study, individuals with the Hpdel
allele did not have a higher incidence of cancer, and
Hpdel does not appear to play a role in carcinogenesis.
Further study of the patients with Hp2/Hpdel should be
done to clarify whether lower Hp levels worsen
prognosis.
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